Enzymatica recruits Chief Commercial Officer
July 18 2017 - 1:30AM
Press release
Lund, 18 July 2017
Enzymatica recruits Chief
Commercial Officer
Enzymatica has recruited Claus
Egstrand as its Chief Commercial Officer. Claus Egstrand's primary
responsibility will be to develop Enzymatica's international
business, focusing on distributor agreements and also, in the
longer term, on the launch of new products. Claus has many years of
experience from pharmaceutical and medical technology companies
such as Merck & Co, Pfizer, Stryker Corporation, Pharmacia and
Johnson&Johnson/Merck Pharmaceuticals.
"There are great growth opportunities for
Enzymatica with its patented barrier technology on which the common
cold spray ColdZyme® is based. I look forward to being able
to contribute with my experience in building successful brands and
international pharmaceutical and medical technology companies. My
aim is to contribute towards Enzymatica becoming a first-class
self-care company in the global market."
"We are delighted to have recruited Claus who,
with his experience and contacts in the life science industry, will
be key to our international expansion, particularly in contact and
negotiations with international partners," says Fredrik Lindberg,
CEO of Enzymatica, continuing:
"Claus has an impressive background, having
repeatedly demonstrated his ability to lead the build-up of
businesses with two-digit growth rates, in terms of both sales and
profits."
Claus Egstrand's previous positions have included
being Head of Europe for MSD Consumer Care in the pharmaceutical
company Merck & Co, Vice President, General Manager Medsurg
Europe in the medical device company Stryker Corporation, Senior
Vice President Consumer Healthcare for Latin America, Africa, Asia,
Japan and Australia in the pharmaceutical company Pfizer, Vice
President and head of global marketing for the smoking cessation
product Nicorette in the pharmaceutical company Pharmacia and CEO
of the Johnson&Johnson/Merck Pharmaceuticals' operation in
France. He joins Enzymatica from a position as Group President,
International at HOLOGIC CORP.
For
more information, contact:
Fredrik Lindberg, CEO of Enzymatica AB
Tel: +46 (0)708-86 53 70, e-mail
fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica AB is a medical device company that develops and sells
medical devices for infection-related diseases. In a short period
of time, the company has developed ColdZyme®, a unique mouth spray
for the common cold, has launched the product in eight markets and
has established it among the top-selling cold products in Swedish
kronor terms at Swedish pharmacies. The strategy is to continue to
grow by strengthening the company's position in existing markets
and expanding into new geographical markets through established
partners. The company is headquartered in Lund and is listed on
Nasdaq First North. For more information,
visit: www.enzymatica.se
Enzymatica's Certified Adviser is Erik Penser Bank.
clausegstrandphoto
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Sep 2024 to Oct 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Oct 2023 to Oct 2024